

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1(Currently amended). An expression vector for the production of an icIL-1ra-II protein beginning at amino acid residue position +2 from the deduced start of translation on the icIL-1ra-II coding sequence, ~~comprising a DNA segment encoding a genomic growth hormone signal peptide with an intron genomic DNA sequence~~, joined to a DNA segment encoding intracellular IL-1 receptor antagonist type II (icIL-1ra-II) and operably linked to a promoter sequence, ~~wherein~~ whereby said icIL-1ra-II is expressed from said promoter sequence ~~and translated with said signal peptide fused in frame to icIL-1ra-II~~ to produce an icIL-1ra-II ~~where~~ with the amino acid sequence of ~~at the N-terminus is~~ SEQ ID NO:11 at the N-terminus.

Claim 2 (Cancelled).

3(Previously presented). An isolated host cell line transformed with the expression vector of claim 1.

Claim 4 (Cancelled).

5 (Previously presented). An isolated host cell line in accordance with claim 3, wherein said cell is an endogenous cell of a human host.

Claim 6 (Cancelled).

7 (Previously presented). A method for producing a recombinant icIL-1ra-II comprising the steps of:

culturing a host cell line according to claim 3 to express and produce a recombinant glycosylated icIL-1ra-II;  
recovering the produced recombinant glycosylated icIL-1ra-II.

Claim 8 (Cancelled).

9 (Currently amended). An isolated ~~glycosylated~~ icIL-1ra-II beginning at amino acid residue position +2 from the deduced start of translation on the icIL-1ra-II coding sequence and having the amino acid sequence of SEQ ID NO:11 at the N-terminus ~~producible by a method according to claim 7.~~

10 (Currently amended). The ~~glycosylated~~ icIL-1ra-II according to claim 9 having an apparent molecular weight of about 27 kDa on SDS-PAGE under reducing conditions with 15% acrylamide.

11 (Currently amended). The ~~glycosylated~~ icIL-1ra-II according to claim 9 having an apparent molecular weight of about 30 kDa on SDS-PAGE under reducing conditions with 15% acrylamide.

12 (Currently amended). A pharmaceutical composition, comprising the ~~glycosylated~~ icIL-1ra-II according to claim 9 in a therapeutically effective amount and a pharmaceutically acceptable excipient.

13 (Withdrawn). A method for reducing the amount of IL-1 in a patient having a condition associated with overexpression of IL-1, comprising administering the pharmaceutical composition according to claim 12 to a patient in need thereof.

14 (Withdrawn). A method for reducing the amount of IL-1 at a desired site in a human patient, comprising introducing a vector in accordance with claim 3 into appropriate endogenous human cells at the desired site to produce transformed cells which will express icIL-1ra-II at the desired site.

Claim 15 and 16 (Cancelled).

17(New). The icIL-1ra-II according to claim 9, which is glycosylated.

Appln. No. 09/807,610

Amd. dated June 4, 2004

Reply to Office Action of January 5, 2004

18(New). The pharmaceutical composition according to claim 12, wherein said icIL-1ra-II is glycosylated.